Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
Current Page:HomeAboutContact
RF EMerge logo

A Resource for Innovators

Topics

GuidanceTrends & AnalysisLegal DevelopmentsSubscribe

Featured

Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy

By Aydin H. Harston, Michael Ellenberger & Stephanie Waltersdorff on April 25, 2025

Introduction: Harnessing Cellular Machinery for Precision Medicine

Targeted protein degradation (TPD) is transforming drug discovery…

Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
mRNA2-3-11-25

mRNA/LNP Patent Litigation Update (Q1 2025)

By Dan Shores on April 9, 2025

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were…

Continue Reading mRNA/LNP Patent Litigation Update (Q1 2025)
4

Key Patent Considerations for Antibody Drug Conjugates (ADCs)

By Dan Shores & Michael Ellenberger on April 8, 2025

In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds…

Continue Reading Key Patent Considerations for Antibody Drug Conjugates (ADCs)
Latest

CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN

By Stephanie Waltersdorff & Aydin H. Harston on March 25, 2025
Posted in Featured, Guidance

Although the Corporate Transparency Act (the “CTA”) is no longer halted by nationwide preliminary injunctions, U.S. companies and their beneficial…

Continue Reading CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN

Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms

By Stephanie Waltersdorff & Aydin H. Harston on February 20, 2025
Posted in Featured, Legal Developments

For the past few months, the beneficial ownership reporting obligations under the Corporate Transparency Act (the “CTA”) have fluctuated between…

Continue Reading Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms

CRISPR and Agriculture

By Sheena Wang on February 7, 2025
Posted in Featured, Trends & Analysis

Co-authored by Sheena Wang and Ellie Purnell of HGF limited, “CRISPR and Agriculture” was originally published by Food and Drink …

Continue Reading CRISPR and Agriculture

Latest Update: Corporate Transparency Act Halted Again

By Aydin H. Harston & Stephanie Waltersdorff on December 28, 2024
Posted in Featured, Legal Developments

Only days after lifting the nationwide preliminary injunction, the Fifth Circuit Court of Appeals vacated their decision to stay the…

Continue Reading Latest Update: Corporate Transparency Act Halted Again

Update: Corporate Transparency Act Reinstated by Appeals Court: January 1 Deadline Looms

By Aydin H. Harston & Stephanie Waltersdorff on December 26, 2024
Posted in Featured, Legal Developments

As an update to our posts on the ongoing attempts to block the Corporate Transparency Act, on December 23, 2024…

Continue Reading Update: Corporate Transparency Act Reinstated by Appeals Court: January 1 Deadline Looms

Update: The Corporate Transparency Act Put On Hold

By Stephanie Waltersdorff on December 19, 2024
Posted in Featured, Legal Developments

As an update to our post on the Corporate Transparency Act, on December 3, 2024, a federal district court issued…

Continue Reading Update: The Corporate Transparency Act Put On Hold

USPTO Finalizes Fee Increases for 2025: What to Expect in the New Year and What to do Now

By Aydin H. Harston & Alex Shaver on November 20, 2024
Posted in Featured, Guidance

The United States Patent and Trademark Office (USPTO) announced today the finalized fee increases taking effect on January 19, 2025.

Continue Reading USPTO Finalizes Fee Increases for 2025: What to Expect in the New Year and What to do Now

Key Inventorship Considerations in AI-assisted Drug Development

By Dan Shores on October 17, 2024
Posted in Featured

The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is…

Continue Reading Key Inventorship Considerations in AI-assisted Drug Development

The Future of Food: Regulatory and Patent Landscape of Genome Editing in Food Technology

By Sheena Wang on October 15, 2024
Posted in Featured, Trends & Analysis

Our current food system is facing a myriad of critical challenges. The United Nations predicts that the world population will…

Continue Reading The Future of Food: Regulatory and Patent Landscape of Genome Editing in Food Technology

The Corporate Transparency Act: What you Need to Know to Comply with the New Requirements

By Aydin H. Harston & Stephanie Waltersdorff on September 24, 2024
Posted in Featured, Guidance

The Corporate Transparency Act (CTA) went into effect on January 1, 2024, and will impact millions of U.S. businesses by…

Continue Reading The Corporate Transparency Act: What you Need to Know to Comply with the New Requirements

Post navigation

Older Posts 
Rothwell, Figg, Ernst & Manbeck, P.C.
Subscribe to this Blog
Washington, DC
901 New York Avenue NW
Suite 900 East
Washington, DC 20001
202.783.6040
emerge@rfem.com
Boston
10 Derne Street
Suite 302
Boston, MA 02114
617.312.3101
emerge@rfem.com
New York
80 South Highland Avenue
Ossining, NY 10562
914.941.5668
emerge@rfem.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit: www.rothwellfigg.com.

Rothwell Figg Blogs

  • Biosimilars Law Bulletin
  • Privacy Zone
  • PTAB Law Blog
  • Trademark Opposition Lawyer
Copyright © 2025, Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo

We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.

Agree